Novartis Targets Teva Over Myfortic Patents

Law360, New York (April 20, 2011, 4:57 PM EDT) -- Novartis AG accused Israeli generics maker Teva Pharmaceutical Industries Ltd. in Delaware on Wednesday of infringing a group of its patents related to immunosuppressive agent Myfortic.

In the lawsuit, filed Wednesday, the Swiss pharmaceutical giant said Teva submitted an abbreviated new drug application to the U.S. Food and Drug Administration that infringes the claims of Novartis' U.S. Patent Numbers 6,025,391; 6,172,107; and 6,306,900, which are all associated with Myfortic.

Drugs like Myfortic are used to protect against organ transplant rejection, but have come under fire in...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.